Motavizumab
Based on 1 Customer Validation
Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research.
For research use only. We do not sell to patients.
- Purity : 99.17%
- CAS No.: 677010-34-3
- Molecular Weight:145.32 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-P9944
PalivizumabRSV Inhibitor -
HY-P99756
NirsevimabAnti-RSV Antibody -
HY-P99804
ClesrovimabAnti-RSV Monoclonal Antibody -
HY-109142
ZiresovirRSV F Inhibitor -
HY-16727
PresatovirRSV Fusion Inhibitor -
HY-12983A
LumicitabineRSV Polymerase Inhibitor -
HY-123475
SisunatovirRSV-F Protein Inhibitor -
HY-P99586
SuptavumabRSV Inhibitor -
HY-120632
BMS-433771RSV Inhibitor -
HY-P9904
AtezolizumabAnti-PD-L1 Antibody -
HY-P9913
RituximabCD20 Inhibitor -
HY-P99103
BebtelovimabSARS-CoV-2 Antibody
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
RSV-F
In Vitro
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Seven-week-old female, pathogen-free BALB/c mice intranasally inoculated with 106.5 PFU RSV-A2[1]
-
Dosage:1.25 mg in 0.1 ml of PBS/per mouse
-
Administration:Intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once
-
Result:Resulted in significant reductions of RSV loads compared with untreated controls on days 1 and 5.
Showed lower BAL concentrations of IL-1α, IL-12p70, TNF-α and IFN-γ and serum IL-10 and KC compared with RSV-infected untreated mice.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Accession
A0A0X8XRK2
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human RSV (A2) Post-fusion glycoprotein F Protein (His Tag) can bind Motavizumab. The EC50 for this effect is 3.866 ng/mL.
Chemical Information
-
CAS No. 677010-34-3
-
Appearance Liquid
-
Molecular Weight 145.32 kDa
-
Color Colorless to light yellow
-
SMILES
[Motavizumab]
-
Synonyms
MEDI-524
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (259 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Mejías A, et al. Motavizumab, a neutralizing anti-Respiratory Syncytial Virus (Rsv) monoclonal antibody significantly modifies the local and systemic cytokine responses induced by Rsv in the mouse model. Virol J. 2007 Oct 25;4:109. [Content Brief]
[2]. Huang K, et al. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. J Virol. 2010 Aug;84(16):8132-40. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Motavizumab Related Classifications
HY-P99209 Related Classifications
Powered by Bioz